Unique epigenetic gene profiles define human breast cancers with poor prognosis

Samuel Peña-Llopis, Yihong Wan, Elisabeth D. Martinez

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Epigenetic enzymes are at the nexus of cellular regulatory cascades and can drive cancer-specific deregulation at all stages of the oncogenic process, yet little is known about their prognostic value in human patients. Here, we used qRT-PCR to profile at high resolution the expression of fifty-five epigenetic genes in over one hundred human breast cancer samples and patient-matched benign tissues. We correlated expression patterns with clinical and histological parameters and validated our findings in two independent large patient cohorts (TCGA and METABRIC). We found that human breast malignancies have unique epigenetic profiles and cluster into epigenetic subgroups. A subset of epigenetic genes defined an Epigenetic Signature as an independent predictor of patient survival that outperforms triple negative status and other clinical variables. Our results also suggest that breast cancer grade, but not stage, is driven by transcriptional alterations of epigenetic modifiers. Overall, this study uncovers the presence of epigenetic subtypes within human mammary malignancies and identifies tumor subgroups with specific pharmacologically targetable epigenetic susceptibilities not yet therapeutically exploited.

Original languageEnglish (US)
Pages (from-to)85819-85831
Number of pages13
JournalOncotarget
Volume7
Issue number52
DOIs
StatePublished - 2016

Fingerprint

Epigenomics
Breast Neoplasms
Genes
Neoplasms
Breast
Polymerase Chain Reaction
Survival
Enzymes

Keywords

  • Epigenetic signature
  • Expression profiles
  • Molecular targets
  • Prognosis
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Unique epigenetic gene profiles define human breast cancers with poor prognosis. / Peña-Llopis, Samuel; Wan, Yihong; Martinez, Elisabeth D.

In: Oncotarget, Vol. 7, No. 52, 2016, p. 85819-85831.

Research output: Contribution to journalArticle

@article{a1299e403b364b6881e44fe66d58b574,
title = "Unique epigenetic gene profiles define human breast cancers with poor prognosis",
abstract = "Epigenetic enzymes are at the nexus of cellular regulatory cascades and can drive cancer-specific deregulation at all stages of the oncogenic process, yet little is known about their prognostic value in human patients. Here, we used qRT-PCR to profile at high resolution the expression of fifty-five epigenetic genes in over one hundred human breast cancer samples and patient-matched benign tissues. We correlated expression patterns with clinical and histological parameters and validated our findings in two independent large patient cohorts (TCGA and METABRIC). We found that human breast malignancies have unique epigenetic profiles and cluster into epigenetic subgroups. A subset of epigenetic genes defined an Epigenetic Signature as an independent predictor of patient survival that outperforms triple negative status and other clinical variables. Our results also suggest that breast cancer grade, but not stage, is driven by transcriptional alterations of epigenetic modifiers. Overall, this study uncovers the presence of epigenetic subtypes within human mammary malignancies and identifies tumor subgroups with specific pharmacologically targetable epigenetic susceptibilities not yet therapeutically exploited.",
keywords = "Epigenetic signature, Expression profiles, Molecular targets, Prognosis, Triple negative breast cancer",
author = "Samuel Pe{\~n}a-Llopis and Yihong Wan and Martinez, {Elisabeth D.}",
year = "2016",
doi = "10.18632/oncotarget.13334",
language = "English (US)",
volume = "7",
pages = "85819--85831",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "52",

}

TY - JOUR

T1 - Unique epigenetic gene profiles define human breast cancers with poor prognosis

AU - Peña-Llopis, Samuel

AU - Wan, Yihong

AU - Martinez, Elisabeth D.

PY - 2016

Y1 - 2016

N2 - Epigenetic enzymes are at the nexus of cellular regulatory cascades and can drive cancer-specific deregulation at all stages of the oncogenic process, yet little is known about their prognostic value in human patients. Here, we used qRT-PCR to profile at high resolution the expression of fifty-five epigenetic genes in over one hundred human breast cancer samples and patient-matched benign tissues. We correlated expression patterns with clinical and histological parameters and validated our findings in two independent large patient cohorts (TCGA and METABRIC). We found that human breast malignancies have unique epigenetic profiles and cluster into epigenetic subgroups. A subset of epigenetic genes defined an Epigenetic Signature as an independent predictor of patient survival that outperforms triple negative status and other clinical variables. Our results also suggest that breast cancer grade, but not stage, is driven by transcriptional alterations of epigenetic modifiers. Overall, this study uncovers the presence of epigenetic subtypes within human mammary malignancies and identifies tumor subgroups with specific pharmacologically targetable epigenetic susceptibilities not yet therapeutically exploited.

AB - Epigenetic enzymes are at the nexus of cellular regulatory cascades and can drive cancer-specific deregulation at all stages of the oncogenic process, yet little is known about their prognostic value in human patients. Here, we used qRT-PCR to profile at high resolution the expression of fifty-five epigenetic genes in over one hundred human breast cancer samples and patient-matched benign tissues. We correlated expression patterns with clinical and histological parameters and validated our findings in two independent large patient cohorts (TCGA and METABRIC). We found that human breast malignancies have unique epigenetic profiles and cluster into epigenetic subgroups. A subset of epigenetic genes defined an Epigenetic Signature as an independent predictor of patient survival that outperforms triple negative status and other clinical variables. Our results also suggest that breast cancer grade, but not stage, is driven by transcriptional alterations of epigenetic modifiers. Overall, this study uncovers the presence of epigenetic subtypes within human mammary malignancies and identifies tumor subgroups with specific pharmacologically targetable epigenetic susceptibilities not yet therapeutically exploited.

KW - Epigenetic signature

KW - Expression profiles

KW - Molecular targets

KW - Prognosis

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85007415647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007415647&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13334

DO - 10.18632/oncotarget.13334

M3 - Article

C2 - 27863398

AN - SCOPUS:85007415647

VL - 7

SP - 85819

EP - 85831

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 52

ER -